Table 3 Communicating COVID-19 related service change information by treatment type
Informing changes | Informed before changes | Informed after changes | Varied patient to patient | Not informed | Missing |
|---|---|---|---|---|---|
Inpatient nephrology | 6 (16.2%) | 16 (43.2%) | 9 (24.3%) | 6 (16.2%) | 10 |
Transition | 7 (25.9%) | 8 (29.6%) | 9 (33.3%) | 3 (11.1%) | 7 |
Mild/moderate CKD | 9 (27.3%) | 13 (39.4%) | 9 (27.3%) | 2 (6.1%) | 5 |
Advanced/low clearance (3b-5) | 9 (23.1%) | 19 (48.7%) | 10 (25.6%) | 1 (2.6%) | 8 |
Immunosuppressed | 10 (25.6%) | 15 (38.5%) | 13 (33.3%) | 1 (2.6%) | 8 |
In-Centre HD | 22 (56.4%) | 14 (35.9%) | 2 (5.1%) | 1 (2.6%) | 8 |
In-Satellite HD | 20 (57.1%) | 13 (37.1%) | 1 (2.9%) | 1 (2.9%) | 7 |
HDD/PD | 18 (46.2%) | 17 (43.6%) | 3 (7.7%) | 1 (2.6%) | 8 |
Assisted PD | 19 (52.8%) | 14 (38.9%) | 1 (2.8%) | 2 (5.6%) | 7 |
Transplant surgery | 7 (50%) | 7 (50%) | 0 (0%) | 0 (0%) | 3 |
Transplant Follow-up | 16 (41%) | 16 (41%) | 7 (17.9%) | 0 (0%) | 7 |
Living donation | 12 (35.3%) | 14 (41.2%) | 7 (20.6%) | 1 (2.9%) | 8 |
Conservative Management | 6 (15.8%) | 13 (34.2%) | 15 (39.5%) | 4 (10.5%) | 9 |
End of Life care | 5 (14.3%) | 10 (28.6%) | 16 (45.7%) | 4 (11.4%) | 7 |